Small cell lung cancer · line 1 · Etoposide-platinum + concurrent thoracic RT (limited SCLC)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | standard |
| Linked regimen | REG-EP-CONCURRENT-RT-SCLC-LIMITED |
| ID | IND-SCLC-LIMITED-1L |
|---|---|
| Type | Indication |
| Status | status not declared |
| Diseases | DIS-SCLC |
| Sources | SRC-ESMO-SCLC-2021 SRC-NCCN-SCLC-2025 |
Notes
Concurrent CRT — superior to sequential. PCI consideration for CR/PR post-CRT.
Used By
Algorithms
ALGO-SCLC-1L- ALGO-SCLC-1L
Indication
IND-SCLC-LS-CONSOLIDATION-DURVA- IND-SCLC-LS-CONSOLIDATION-DURVA